|By PR Newswire||
|January 21, 2014 01:42 PM EST||
CHICAGO, Jan. 21, 2014 /PRNewswire/ -- Cour Pharmaceutical Development Company, Inc., a biopharmaceutical company, announced today the publication of new data in Science Translational Medicine that shows the potential of its proprietary therapy, known as Immune Modifying Nanoparticles (IMP), to reduce inflammation and promote tissue repair and regeneration in patients who have suffered a heart attack. More than 750,000 patients suffer from heart attacks & related complications each year.
When animal models were injected with IMPs after a heart attack, the size of the heart lesions were reduced by 50 percent allowing the heart to pump significantly more blood. IMP treatment showed reduced inflammation and promoted regeneration in all models tested.
"This is the first therapy that specifically targets a key driver of the inflammation that occurs after a heart attack," said Daniel Getts, Chief Scientific Officer at Cour. "There is no other therapy on the horizon that can protect the heart from the aggressive immune cell infiltration that causes so much damage."
Originally discovered in the laboratory of Professor Nicholas King, at the University of Sydney, the particles are proprietary compositions based on poly-lactic-co-glycolic acid, a biocompatible and biodegradable substance already approved by the Food and Drug Administration for use in a range of therapeutics.
"IMP therapy represents a significant step toward the next generation of immune modulating agents," said John J. Puisis, CEO of Cour. He added, "Our first priority as a company is to bring IMPs to patients who've suffered acute myocardial infarction, where we see a tremendous opportunity to improve clinical outcomes and quality of life."
The therapy also showed efficacy in numerous other inflammatory models, specifically in West Nile Virus, Encephalitis, Peritonitis, Multiple Sclerosis, and Inflammatory Bowel Disease - all with the potential to benefit patients suffering from these inflammatory diseases.
Getts and King are corresponding authors on the paper, which was published January 15, 2014 in Science Translational Medicine.
For more information, visit www.courpharma.com
SOURCE Cour Pharmaceutical Development Company, Inc.
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
Jul. 27, 2016 12:00 AM EDT Reads: 1,989
Basho Technologies has announced the latest release of Basho Riak TS, version 1.3. Riak TS is an enterprise-grade NoSQL database optimized for Internet of Things (IoT). The open source version enables developers to download the software for free and use it in production as well as make contributions to the code and develop applications around Riak TS. Enhancements to Riak TS make it quick, easy and cost-effective to spin up an instance to test new ideas and build IoT applications. In addition to...
Jul. 27, 2016 12:00 AM EDT Reads: 1,926
Jul. 26, 2016 11:30 PM EDT Reads: 1,731
Jul. 26, 2016 11:00 PM EDT Reads: 1,997
Jul. 26, 2016 11:00 PM EDT Reads: 2,558
Jul. 26, 2016 10:45 PM EDT Reads: 1,355
Jul. 26, 2016 10:45 PM EDT Reads: 1,086
Jul. 26, 2016 10:30 PM EDT Reads: 1,358
Jul. 26, 2016 10:15 PM EDT Reads: 1,979
Jul. 26, 2016 09:00 PM EDT Reads: 2,031
Jul. 26, 2016 08:30 PM EDT Reads: 2,133
Jul. 26, 2016 08:00 PM EDT Reads: 315
Jul. 26, 2016 07:15 PM EDT Reads: 1,931
Jul. 26, 2016 07:00 PM EDT Reads: 1,797
Jul. 26, 2016 06:30 PM EDT Reads: 2,122